Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil + bosentan combination therapy in severe pulmonary hypertension
2009-017155-10Phase 3Completed
- Sponsor
- IRCCS San Raffaele Pisana
- Start
- Dec 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sildenafil and bosentan in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by IRCCS San Raffaele Pisana. Primary endpoints: Improvement in functional capacity, Improvement in quality of life and 1 more. Started Dec 2011; status: completed.
02
Drugs
sildenafilbosentan
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2009-017155-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017155-10.